These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36442210)
1. Monoclonal Antibodies in Neurodegenerative Disease May Work, But They Don't Help: A Perspective from Physicians. Richard E; Bloem BR J Parkinsons Dis; 2022; 12(8):2289-2291. PubMed ID: 36442210 [No Abstract] [Full Text] [Related]
2. Prasinezumab and Cinpanemab - The Perspective of a Person with Parkinson's. McFarthing K J Parkinsons Dis; 2022; 12(8):2287-2288. PubMed ID: 36373296 [No Abstract] [Full Text] [Related]
3. Trial of Cinpanemab in Early Parkinson's Disease. Lang AE; Siderowf AD; Macklin EA; Poewe W; Brooks DJ; Fernandez HH; Rascol O; Giladi N; Stocchi F; Tanner CM; Postuma RB; Simon DK; Tolosa E; Mollenhauer B; Cedarbaum JM; Fraser K; Xiao J; Evans KC; Graham DL; Sapir I; Inra J; Hutchison RM; Yang M; Fox T; Budd Haeberlein S; Dam T; N Engl J Med; 2022 Aug; 387(5):408-420. PubMed ID: 35921450 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. Teng JS; Ooi YY; Chye SM; Ling APK; Koh RY CNS Neurol Disord Drug Targets; 2021; 20(9):802-813. PubMed ID: 34042040 [TBL] [Abstract][Full Text] [Related]
5. Detection of α-Synuclein-Specific T Cells in Parkinson's Disease. Dhanwani R; Sette A; Lindestam Arlehamn CS Methods Mol Biol; 2022; 2574():123-131. PubMed ID: 36087199 [TBL] [Abstract][Full Text] [Related]
6. [Aggregation and spread of synuclein in Parkinson's disease]. Bezard E; Dehay B Med Sci (Paris); 2022 Jan; 38(1):45-51. PubMed ID: 35060886 [TBL] [Abstract][Full Text] [Related]
7. Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain. Kuchimanchi M; Monine M; Kandadi Muralidharan K; Woodward C; Penner N CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):515-522. PubMed ID: 32613752 [TBL] [Abstract][Full Text] [Related]
8. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease. Wang Z; Gao G; Duan C; Yang H Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
11. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. Giasson BI; Jakes R; Goedert M; Duda JE; Leight S; Trojanowski JQ; Lee VM J Neurosci Res; 2000 Feb; 59(4):528-33. PubMed ID: 10679792 [TBL] [Abstract][Full Text] [Related]
12. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. Castonguay AM; Gravel C; Lévesque M J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039 [TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088 [TBL] [Abstract][Full Text] [Related]
14. Getting in charge of β-synuclein fibrillation. Landau M J Biol Chem; 2017 Sep; 292(39):16380-16381. PubMed ID: 28963338 [TBL] [Abstract][Full Text] [Related]
15. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422 [TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection. Lee HJ; Kim C; Lee SJ Oxid Med Cell Longev; 2010; 3(4):283-7. PubMed ID: 20972375 [TBL] [Abstract][Full Text] [Related]